Castrate resistant Prostate Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, Companies by DelveInsight

DelveInsight's, "Castrate Resistant Prostate Cancer Pipeline Insight" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Castrate Resistant Prostate Cancer pipeline landscape. It covers the Castrate Resistant Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Castrate Resistant Prostate Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Castrate Resistant Prostate Cancer Pipeline Report to explore emerging therapies, key Castrate Resistant Prostate Cancer Companies, and future Castrate Resistant Prostate Cancer treatment landscapes @ Castrate Resistant Prostate Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Castrate Resistant Prostate Cancer Pipeline Report

* In February 2025:- Daniel George, MD- The primary goal is to prospectively estimate the median PFS of African American and Caucasian men with mCRPC taking apalutamide, abiraterone acetate, and prednisone. Secondary objectives include: PSA kinetics: to determine the duration of PSA response, time to nadir, and percent of men who achieve a PSA < 0.1; Radiographic assessments: to estimate the rate of objective response and incidence of bone flares; Safety (NCI CTC v4.0) and tolerability, particularly incidence and grade of hypertension in the two populations.
* In February 2025:- Alliance Foundation Trials, LLC.:- This is a prospective, randomized, open-label phase II study comparing cognitive outcomes between men with metastatic and non-metastatic castration resistant prostate cancer (CRPC) or metastatic hormone sensitive prostate cancer (HSPC). Approximately 132 patients will be enrolled. Eligible patients will be randomized in a 1:1 fashion to treatment with enzalutamide 160 mg orally daily or darolutamide 600 mg orally twice daily, in combination with standard LHRH agonist based treatment. Cognitive assessments will be performed using modules from Cambridge Neuropsychological Test Automated Battery (CANTAB) an internationally recognized software for assessing cognitive function and impairment.
* In February 2025:- Dana-Farber Cancer Institute:- This study is comparing the safety and effectiveness of abiraterone acetate alone, followed by the addition of prednisone (when the participant's disease worsens or the physician feels it would lessen symptoms of toxicity) versus the current approved treatment regimen which involves the concomitant use of prednisone in conjunction with abiraterone acetate. Additionally, this study is also examining why participants stop responding to treatment with abiraterone acetate by evaluating blood and tissue.
* DelveInsight's Castrate Resistant Prostate Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Castrate Resistant Prostate Cancer treatment.
* The leading Castrate Resistant Prostate Cancer Companies such as Janssen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma and others.
* Promising Castrate Resistant Prostate Cancer pipeline therapies such as AZD4635, Durvalumab, Cabazitaxel, tomivosertib (eFT508), Atezolizumab, Radium-223 Dichloridem , and others.

Discover how the Castrate Resistant Prostate Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Castrate Resistant Prostate Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Castrate Resistant Prostate Cancer Clinical Trials and Studies [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Castrate Resistant Prostate Cancer Emerging Drugs

* Niraparib: Janseen

Niraparib is highly selective poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, with potent activity against PARP-1 and PARP-2 deoxyribonucleic acid (DNA)-repair polymerases. Niraparib is currently investigated by Janssen Research & Development.

* Nivolumab: Bristol-Myers Squibb

Nivolumab by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. BMS is working on assessing the clinical activity seen with Nivolumab in combination with docetaxel in male patients with metastatic castration-resistant prostate cancer.

The Castrate Resistant Prostate Cancer pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Castrate Resistant Prostate Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Castrate Resistant Prostate Cancer Treatment.
* Castrate Resistant Prostate Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Castrate Resistant Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Castrate Resistant Prostate Cancer market.

Get a detailed analysis of the latest innovations in the Castrate Resistant Prostate Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Castrate Resistant Prostate Cancer Unmet Needs [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Castrate Resistant Prostate Cancer Companies

Janssen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma and others.

Castrate Resistant Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Parenteral
* intravitreal
* Subretinal
* Topical.
* Molecule Type

Castrate Resistant Prostate Cancer Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type

Download DelveInsight's latest report to gain strategic insights into upcoming Castrate Resistant Prostate Cancer Therapies and key Castrate Resistant Prostate Cancer Developments @ Castrate Resistant Prostate Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Castrate Resistant Prostate Cancer Pipeline Report

* Coverage- Global
* Castrate Resistant Prostate Cancer Companies- Janssen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma and others.
* Promising Castrate Resistant Prostate Cancer pipeline therapies such as AZD4635, Durvalumab, Cabazitaxel, tomivosertib (eFT508), Atezolizumab, Radium-223 Dichloridem, and others.
* Castrate Resistant Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Castrate Resistant Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Castrate Resistant Prostate Cancer drug development? Find out in DelveInsight's exclusive Castrate Resistant Prostate Cancer Pipeline Report-access it now! @ Castrate Resistant Prostate Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Castrate Resistant Prostrate Cancer: Overview
* Causes
* Mechanism of Action
* Signs and Symptoms
* Diagnosis
* Disease Management
* Pipeline Therapeutics
* Comparative Analysis
* Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
* Castrate Resistant Prostrate Cancer - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Castrate Resistant Prostrate Cancer companies' collaborations, Licensing, Acquisition -Deal Value Trends
* Castrate Resistant Prostrate Cancer Collaboration Deals
* Company-Company Collaborations (Licensing / Partnering) Analysis
* Company-University Collaborations (Licensing / Partnering) Analysis
* Late Stage Products (Phase III)
* Comparative Analysis
* Niraparib: Janseen
* Product Description
* Research and Development
* Product Development Activities
* Mid Stage Products (Phase II)
* Comparative Analysis
* ZEN003694: Newsoara Biopharma
* Product Description
* Research and Development
* Product Development Activities
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Comparative Analysis
* EPI7386: ESSA Pharma
* Product Description
* Research and Development
* Product Development Activities
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* Comparative Analysis
* Drug Name: Company Name
* Product Description
* Research and Development
* Product Development Activities
* Drug profiles in the detailed report.....
* Inactive Products
* Comparative Analysis
* Castrate Resistant Prostrate Cancer Key Companies
* Castrate Resistant Prostrate Cancer Key Products
* Castrate Resistant Prostrate Cancer- Unmet Needs
* Castrate Resistant Prostrate Cancer- Market Drivers and Barriers
* Castrate Resistant Prostrate Cancer- Future Perspectives and Conclusion
* Castrate Resistant Prostrate Cancer Analyst Views
* Castrate Resistant Prostrate Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=castrate-resistant-prostate-cancer-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-companies-by-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/sepsis-market-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.